Table 3.
Details of Non-major Bleeding Episodes
| Patient | Age | Sex | Medication Dose Appropriate (Y/N) |
Site of Bleeding | Platelet Count at the time of bleeding |
Concomitant anti-platelet therapy |
GFR at initiation of DOAC |
GFR at the time of bleed |
Anticoagulation (Continued/ Discontinued) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 82 | M | Dabigatran 150 mg bid (Y) |
Hematuria | 230 | N | 76 | 71 | Discontinued transiently, currently on rivaroxaban |
| 2 | 75 | F | Dabigatran 150 mg bid (Y) |
Hematuria | 221 | N | 78 | 72 | Discontinued |
| 3 | 91 | F | Rivaroxaban 15 mg daily (Y) |
Epistaxis | 175 | N | 47 | 33 | Discontinued |
| 4 | 89 | M | Rivaroxaban 15 mg daily (N) |
Recurrent epistaxis |
Not checked |
N | >90 | Not checked |
Continued |
| 5 | 91 | M | Dabigatran 150 mg bid (N) |
Hematochezia | 161 | N | 55 | 47 | Continued |
| 6 | 86 | F | Dabigatran 75 mg bid (Y) |
Vaginal bleeding |
147 | N | 46 | 47 | Switched to coumadin |
| 7 | 89 | F | Apixaban 2.5 mg bid (Y) |
Intermittent hematuria |
Not checked |
N | 79 | Not checked |
Continued |
| 8 | 79 | M | Rivaroxaban 20 mg daily (Y) |
Epistaxis | 174 | N | 77 | 86 | Continued |
| 9 | 75 | F | Rivaroxaban 20 mg daily (Y) |
Easy bruising | Not checked |
N | 70 | 55 | Switched to coumadin |
| 10 | 81 | F | Rivaroxaban 20 mg daily (Y) |
Vaginal bleeding |
195 | N | >90 | >90 | Switched to apixaban |
| 11 | 76 | M | Rivaroxaban 15 mg daily (N) |
Subconjunctival hemorrhage |
163 | Y | 63 | 68 | Continued |
| 12 | 84 | F | Rivaroxaban 20 mg daily (Y) |
Recurrent Epistaxis |
Not checked |
N | 42 | Not checked |
Continued |